Kate F. Byth

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

Robert W. Wilkinson, Rajesh Odedra, Simon P. Heaton et al. · Clinical Cancer Research · 2007 · 355 citations · Full text

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft et al. · Oncotarget · 2017 · 149 citations · Full text

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6

William McCoull, Tony Cheung, Erica Anderson et al. · ACS Chemical Biology · 2018 · 133 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, B-cell Lymphoma 6 +14

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Kate F. Byth, Andrew P. Thomas, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2009 · 121 citations

Imidazo[1,2- a ]pyridines. Part 2 : SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors

Kate F. Byth, Janet D. Culshaw, Stephen Green et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 112 citations · Full text

Cyclin-dependent Kinase Inhibitors, Medicinal Chemistry, Heterocyclic +9